There is one clinical trial.
Observe the efficacy and safety of G1(Sildenafil citrate tablets) in patients with COVID-19 under clinical actual diagnosis and treatment conditions
Description: fever,cough and other symptoms relieved with improved lung CT; SPO2>93% or PaO2/FiO2 >300mmHg without oxygen inhalation.Measure: Rate of disease remission Time: 14 days
Description: Comply with any of the followings: Respiratory failure occurs and requires mechanical ventilation; Shock; Patients combined with other organ failure need ICU monitoring and treatment.Measure: Rate of entering the critical stage Time: 14 days
Description: Comply with any of the followings: Respiratory failure occurs and requires mechanical ventilation; Shock; Patients combined with other organ failure need ICU monitoring and treatment.Measure: Time of entering the critical stage Time: 14 days
Description: From the date of enrollment to the time when the subject is released from the hospital or transferred to the corresponding department for treatment of other diseases according to the condition.Measure: Time for hospitalization Time: 14 days
Description: All adverse events will be coded and described using the International Medical Terms Dictionary (MedDRA).Measure: Rate of adverse event Time: 14 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports